{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:43:19Z","timestamp":1790790199917,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T00:00:00Z","timestamp":1648339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T00:00:00Z","timestamp":1648339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pulmonary involvement in individuals with transthyretin cardiac amyloidosis is unclear. The aim of this study was to quantify <jats:sup>99m<\/jats:sup>Tc-hydroxy methylene diphosphonate (HMDP) lung retention in hereditary transthyretin (ATTRv) cardiac amyloidosis patients and to relate tracer uptake intensity to pulmonary function and aerobic capacity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We prospectively enrolled 20 patients with biopsy-proven ATTRv cardiac amyloidosis and 20 control subjects. Cardiac involvement was confirmed by echocardiography and nuclear imaging using <jats:sup>99m<\/jats:sup>Tc-HMDP. Semi-quantitative analysis of the heart, rib and lung retention was assessed using a simple region of interest technique. Pulmonary function was evaluation by the means of whole-body plethysmography, diffusing capacity of the lung for carbon monoxide, forced oscillation technique and cardiopulmonary exercise testing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Pulmonary tracer uptake estimated by lung to rib retention ratio was higher in ATTRv amyloidosis patients compared with control subjects: median 0.62 (0.55\u20130.69) vs 0.51 (0.46\u20130.60); p\u2009=\u20090.014. Analysis of relation between lung <jats:sup>99m<\/jats:sup>Tc-HMDP retention and pulmonary function parameters shown statistically significant correlations with total lung volume (% predicted), lung reactance (X<jats:sub>rs<\/jats:sub> 5\u00a0Hz) and peak VO<jats:sub>2<\/jats:sub>, suggesting total lung capacity restriction impaired elastic properties of the lung and poor aerobic capacity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our study suggests that some grade of pulmonary retention of <jats:sup>99m<\/jats:sup>Tc-HMDP may occur in patients with cardiac ATTRv amyloidosis, which can elicit deleterious effects on patient\u2019s lung function and aerobic capacity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-022-01995-x","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T12:09:05Z","timestamp":1648469345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pulmonary 99mTc-HMDP uptake correlates with restrictive ventilatory defects and abnormal lung reactance in transthyretin cardiac amyloidosis patients"],"prefix":"10.1186","volume":"23","author":[{"given":"Astrid","family":"Monfort","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishika","family":"Banydeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Inamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Farid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7966-0110","authenticated-orcid":false,"given":"Remi","family":"Neviere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,27]]},"reference":[{"issue":"1","key":"1995_CR1","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","volume":"142","author":"MM Kittleson","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142(1):e7-22.","journal-title":"Circulation"},{"key":"1995_CR2","doi-asserted-by":"crossref","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology working group on myocardial and pericardial diseases. Eur J Heart Fail. 2021;23(4):512\u201326.","DOI":"10.1002\/ejhf.2140"},{"issue":"1","key":"1995_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jama.2020.5493","volume":"324","author":"MA Gertz","year":"2020","unstructured":"Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review. JAMA. 2020;324(1):79\u201389.","journal-title":"JAMA"},{"issue":"2","key":"1995_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nrcardio.2014.165","volume":"12","author":"MA Gertz","year":"2015","unstructured":"Gertz MA, Dispenzieri A, Sher T. Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol. 2015;12(2):91\u2013102.","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"1995_CR5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/joim.13169","volume":"289","author":"E Muchtar","year":"2021","unstructured":"Muchtar E, Dispenzieri A, Magen H, Grogan M, Mauermann M, McPhail ED, et al. Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med. 2021;289(3):268\u201392.","journal-title":"J Intern Med"},{"key":"1995_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-021-10164-z","author":"S Arno","year":"2021","unstructured":"Arno S, Cowger J. The genetics of cardiac amyloidosis. Heart Fail Rev. 2021. https:\/\/doi.org\/10.1007\/s10741-021-10164-z.","journal-title":"Heart Fail Rev"},{"issue":"2","key":"1995_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.5858\/arpa.2016-0102-RA","volume":"141","author":"A Khoor","year":"2017","unstructured":"Khoor A, Colby TV. Amyloidosis of the lung. Arch Pathol Lab Med. 2017;141(2):247\u201354.","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"1995_CR8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s00259-017-3814-1","volume":"45","author":"N Ezawa","year":"2018","unstructured":"Ezawa N, Katoh N, Oguchi K, Yoshinaga T, Yazaki M, Sekijima Y. Visualization of multiple organ amyloid involvement in systemic amyloidosis using 11C-PiB PET imaging. Eur J Nucl Med Mol Imaging. 2018;45(3):452\u201361.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1995_CR9","doi-asserted-by":"crossref","unstructured":"Milani P, Basset M, Russo F, Foli A, Palladini G, Merlini G. The lung in amyloidosis. Eur Respir Rev. 2017;26(145):170046.","DOI":"10.1183\/16000617.0046-2017"},{"issue":"2","key":"1995_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1055\/s-0040-1708059","volume":"41","author":"M Baqir","year":"2020","unstructured":"Baqir M, Roden AC, Moua T. Amyloid in the lung. Semin Respir Crit Care Med. 2020;41(2):299\u2013310.","journal-title":"Semin Respir Crit Care Med"},{"issue":"1","key":"1995_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/13506129.2017.1301917","volume":"24","author":"P Govender","year":"2017","unstructured":"Govender P, Keyes CM, Hankinson EA, O\u2019Hara CJ, Sanchorawala V, Berk JL. Transbronchial biopsies safely diagnose amyloid lung disease. Amyloid. 2017;24(1):37\u201341.","journal-title":"Amyloid"},{"issue":"4","key":"1995_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/1479972306070066","volume":"3","author":"HJ Lachmann","year":"2006","unstructured":"Lachmann HJ, Hawkins PN. Amyloidosis and the lung. Chron Respir Dis. 2006;3(4):203\u201314.","journal-title":"Chron Respir Dis"},{"key":"1995_CR13","doi-asserted-by":"publisher","first-page":"874","DOI":"10.12659\/AJCR.900682","volume":"17","author":"AE Revelo","year":"2016","unstructured":"Revelo AE, Magaspi C, Maguire G, Aronow WS. Hereditary amyloidosis with recurrent lung infiltrates. Am J Case Rep. 2016;17:874\u20139.","journal-title":"Am J Case Rep"},{"issue":"1","key":"1995_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/13506120500537194","volume":"13","author":"M Ueda","year":"2006","unstructured":"Ueda M, Ando Y, Haraoka K, Katsuragi S, Terasaki Y, Sugimoto M, et al. Aging and transthyretin-related amyloidosis: pathologic examinations in pulmonary amyloidosis. Amyloid. 2006;13(1):24\u201330.","journal-title":"Amyloid"},{"issue":"2","key":"1995_CR15","doi-asserted-by":"publisher","first-page":"1602313","DOI":"10.1183\/13993003.02313-2016","volume":"49","author":"K Ussavarungsi","year":"2017","unstructured":"Ussavarungsi K, Yi ES, Maleszewski JJ, Kurtin PJ, Dasari S, Theis JD, et al. Clinical relevance of pulmonary amyloidosis: an analysis of 76 autopsy-derived cases. Eur Respir J. 2017;49(2):1602313.","journal-title":"Eur Respir J"},{"key":"1995_CR16","doi-asserted-by":"crossref","unstructured":"Utz JP, Swensen SJ, Gertz MA. Pulmonary amyloidosis. The Mayo Clinic experience from 1980 to 1993. Ann Intern Med. 1996;124(4):407\u201313.","DOI":"10.7326\/0003-4819-124-4-199602150-00004"},{"issue":"3","key":"1995_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/cpf.12219","volume":"36","author":"T Bach-Gansmo","year":"2016","unstructured":"Bach-Gansmo T, Wien TN, L\u00f8ndalen A, Halvorsen E. Myocardial uptake of bone scintigraphic agents associated with increased pulmonary uptake. Clin Physiol Funct Imaging. 2016;36(3):237\u201341.","journal-title":"Clin Physiol Funct Imaging"},{"key":"1995_CR18","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ijcard.2017.10.027","volume":"254","author":"F Cappelli","year":"2018","unstructured":"Cappelli F, Gallini C, Costanzo EN, Tutino F, Ciaccio A, Vaggelli L, et al. Lung uptake during 99mTc-hydroxymethylene diphosphonate scintigraphy in patient with TTR cardiac amyloidosis: an underestimated phenomenon. Int J Cardiol. 2018;254:346\u201350.","journal-title":"Int J Cardiol"},{"issue":"4","key":"1995_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3109\/13506129.2015.1072089","volume":"22","author":"A Galat","year":"2015","unstructured":"Galat A, Rosso J, Guellich A, Van Der Gucht A, Rappeneau S, Bodez D, et al. Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis. Amyloid. 2015;22(4):210\u201320.","journal-title":"Amyloid"},{"issue":"11","key":"1995_CR20","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/ehjci\/jeu107","volume":"15","author":"DF Hutt","year":"2014","unstructured":"Hutt DF, Quigley A-M, Page J, Hall ML, Burniston M, Gopaul D, et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014;15(11):1289\u201398.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"3","key":"1995_CR21","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s00259-001-0730-0","volume":"29","author":"M Puille","year":"2002","unstructured":"Puille M, Altland K, Linke RP, Steen-M\u00fcller MK, Kiett R, Steiner D, et al. 99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur J Nucl Med Mol Imaging. 2002;29(3):376\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1995_CR22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13550-018-0425-1","volume":"8","author":"L Baratto","year":"2018","unstructured":"Baratto L, Park SY, Hatami N, Gulaka P, Vasanawala S, Yohannan TK, et al. 18F-florbetaben whole-body PET\/MRI for evaluation of systemic amyloid deposition. EJNMMI Res. 2018;8(1):66.","journal-title":"EJNMMI Res"},{"issue":"9","key":"1995_CR23","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","volume":"41","author":"S Dorbala","year":"2014","unstructured":"Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR, Di Carli MF, et al. Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41(9):1652\u201362.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"1995_CR24","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.2967\/jnumed.118.221770","volume":"60","author":"EC Ehman","year":"2019","unstructured":"Ehman EC, El-Sady MS, Kijewski MF, Khor YM, Jacob S, Ruberg FL, et al. Early detection of multiorgan light-chain amyloidosis by whole-body 18F-florbetapir PET\/CT. J Nucl Med. 2019;60(9):1234\u20139.","journal-title":"J Nucl Med"},{"issue":"8","key":"1995_CR25","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1007\/s00259-019-04627-7","volume":"47","author":"YM Khor","year":"2020","unstructured":"Khor YM, Cuddy S, Harms HJ, Kijewski MF, Park M-A, Robertson M, et al. Quantitative 18F florbetapir PET\/CT may identify lung involvement in patients with systemic AL amyloidosis. Eur J Nucl Med Mol Imaging. 2020;47(8):1998\u20132009.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1995_CR26","doi-asserted-by":"crossref","unstructured":"Sperry BW, Bock A, DiFilippo FP, Donnelly JP, Hanna M, Jaber WA. Pilot study of F18-florbetapir in the early evaluation of cardiac amyloidosis. Front Cardiovasc Med. 2021;8:693194.","DOI":"10.3389\/fcvm.2021.693194"},{"issue":"7","key":"1995_CR27","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s00259-018-3995-2","volume":"45","author":"T Wagner","year":"2018","unstructured":"Wagner T, Page J, Burniston M, Skillen A, Ross JC, Manwani R, et al. Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds. Eur J Nucl Med Mol Imaging. 2018;45(7):1129\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1995_CR28","doi-asserted-by":"crossref","unstructured":"Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med. 2019;200(8):e70\u201388.","DOI":"10.1164\/rccm.201908-1590ST"},{"issue":"6","key":"1995_CR29","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1183\/09031936.03.00089403","volume":"22","author":"E Oostveen","year":"2003","unstructured":"Oostveen E, MacLeod D, Lorino H, Farr\u00e9 R, Hantos Z, Desager K, et al. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J. 2003;22(6):1026\u201341.","journal-title":"Eur Respir J"},{"issue":"1","key":"1995_CR30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1183\/09031936.96.09010132","volume":"9","author":"HG Pasker","year":"1996","unstructured":"Pasker HG, Schepers R, Cl\u00e9ment J, Van de Woestijne KP. Total respiratory impedance measured by means of the forced oscillation technique in subjects with and without respiratory complaints. Eur Respir J. 1996;9(1):131\u20139.","journal-title":"Eur Respir J"},{"key":"1995_CR31","doi-asserted-by":"crossref","unstructured":"American Thoracic Society, American College of Chest Physicians. ATS\/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003;167(2):211\u201377.","DOI":"10.1164\/rccm.167.2.211"},{"issue":"2","key":"1995_CR32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1164\/rccm.201112-2160CI","volume":"186","author":"JMB Hughes","year":"2012","unstructured":"Hughes JMB, Pride NB. Examination of the carbon monoxide diffusing capacity (DL(CO)) in relation to its KCO and VA components. Am J Respir Crit Care Med. 2012;186(2):132\u20139.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-01995-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-022-01995-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-01995-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T06:02:05Z","timestamp":1699682525000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-022-01995-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,27]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1995"],"URL":"https:\/\/doi.org\/10.1186\/s12931-022-01995-x","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,27]]},"assertion":[{"value":"28 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our manuscript includes a statement on ethics approval and consent and the name of the ethics committee that approved the study and the committee\u2019s reference number. An Institutional Review Board (IRB) has been obtained (IRB 00006477, APHP, France).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication\u2019"}},{"value":"Authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The lead author NEVIERE Remi affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. Signed by: NEVIERE Remi *The manuscript\u2019s guarantor.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of transparency"}}],"article-number":"72"}}